查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1402925

術後噁心嘔吐市場 - 全球產業分析、規模、佔有率、成長、趨勢和預測，2023-2031 年

Post-operative Nausea and Vomiting Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2023-2031
出版日期: | 出版商: Transparency Market Research | 英文 166 Pages | 商品交期: 2-10個工作天內

價格

術後噁心和嘔吐 (PONV) 市場 - 報告範圍

TMR 關於全球術後噁心嘔吐 (PONV) 市場的報告研究了過去和當前的成長趨勢以及機會，以獲得 2023 年至 2031 年預測期內市場指標的寶貴見解。該報告提供了收入2017-2031 年全球術後噁心嘔吐(PONV) 市場規模，以2023 年為基準年，2031 年為預測年。報告中也提供了2023年至2031年全球術後噁心嘔吐（PONV）市場的年複合成長率（CAGR %）。

該報告是經過廣泛研究後編寫的。初級研究涉及大部分研究工作，其中分析師對關鍵意見領袖、行業領導者和輿論製造者進行了採訪。二次研究涉及參考主要參與者的產品文獻、年度報告、新聞稿和相關文件，以了解術後噁心嘔吐 (PONV) 市場。

市場概況
2023年市場價值 21 億美元
2031 年市場價值 40 億美元
CAGR 7.4%

該報告深入研究了全球術後噁心嘔吐（PONV）市場的競爭格局。全球術後噁心嘔吐 (PONV) 市場的主要參與者已被確定，並且每位參與者都已根據各種屬性進行了分析。公司概述、財務狀況、最新發展和 SWOT 是本報告中介紹的全球術後噁心嘔吐 (PONV) 市場參與者的屬性。

目錄

第 1 章：執行摘要

第 2 章：假設與研究方法

第 3 章：執行摘要：全球市場

第 4 章：市場概述

  • 市場區隔
  • 概述
  • 市場動態
  • 2022-2031年全球市場分析與預測

第 5 章：關鍵見解

  • 管道分析
  • COVID-19 大流行對該行業的影響

第 6 章：市場分析與預測：依治療類型

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：依治療類型，2023-2031
    • 5-羥色胺拮抗劑
    • 類固醇
    • 多巴胺拮抗劑
    • NK-1 受體拮抗劑
    • 非藥物治療
    • 其他
  • 市場吸引力：按治療類型

第 7 章：全球市場分析與預測：按配銷通路

  • 簡介和定義
  • 主要發現/進展
  • 市場價值預測：按配銷通路，2023-2031
    • 醫院藥房
    • 網路藥局
    • 零售藥局和藥局
  • 市場吸引力：按配銷通路

第 8 章：全球市場分析與預測：按地區

  • 主要發現
  • 市場價值預測：按地區，2023-2031
    • 北美洲
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲
  • 市場吸引力：按地區

第 9 章：北美市場分析與預測

第 10 章：歐洲市場分析與預測

第 11 章：亞太市場分析與預測

第 12 章：拉丁美洲市場分析與預測

第 13 章：中東和非洲市場分析與預測

第 14 章：競爭格局

  • 市場參與者 - 競爭矩陣（依公司層級和規模）
  • 市佔率分析：依公司分類（2022 年）
  • 公司簡介
    • Acacia Pharma
    • F. Hoffmann-La Roche AG
    • Novartis AG
    • Ani Pharmaceuticals, Inc.
    • Camurus AB
    • Sanofi SA
    • Helsinn Holding SA
    • Eisai Corporation
    • GlaxoSmithKline Corporation
    • Merck and Co.
Product Code: TMRGL2969

Post-operative Nausea and Vomiting (PONV) Market - Scope of Report

TMR's report on the global post-operative nausea and vomiting (PONV) market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global post-operative nausea and vomiting (PONV) market for the period 2017-2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global post-operative nausea and vomiting (PONV) market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the post-operative nausea and vomiting (PONV) market.

Market Snapshot
Market Value in 2023US$ 2.1 Bn
Market Value in 2031US$ 4 Bn
CAGR7.4%

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global post-operative nausea and vomiting (PONV) market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global post-operative nausea and vomiting (PONV) market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global post-operative nausea and vomiting (PONV) market.

The report delves into the competitive landscape of the global post-operative nausea and vomiting (PONV) market. Key players operating in the global post-operative nausea and vomiting (PONV) market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global post-operative nausea and vomiting (PONV) market profiled in this report.

Key Questions Answered in Global post-operative nausea and vomiting (PONV) Market Report:

  • What is the sales/revenue generated by post-operative nausea and vomiting (PONV) across all regions during the forecast period?
  • What are the opportunities in the global post-operative nausea and vomiting (PONV) market?
  • What are the major drivers, restraints, opportunities, and threats in the market?
  • Which regional market is set to expand at the fastest CAGR during the forecast period?
  • Which segment is expected to generate the highest revenue globally in 2031?
  • Which segment is projected to expand at the highest CAGR during the forecast period?
  • What are the market positions of different companies operating in the global market?

Post-operative Nausea and Vomiting (PONV) Market - Research Objectives and Research Approach

The comprehensive report on the global post-operative nausea and vomiting (PONV) market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global post-operative nausea and vomiting (PONV) market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global post-operative nausea and vomiting (PONV) market.

Table of Contents

1. Executive Summary

  • 1.1. Market Definition and Scope
  • 1.2. Market Segmentation
  • 1.3. Key Research Objectives
  • 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Post-operative Nausea and Vomiting (PONV) Market

4. Market Overview

  • 4.1. Market Segmentation
    • 4.1.1. Segment Definition
    • 4.1.2. Industry Evolution / Developments
  • 4.2. Overview
  • 4.3. Market Dynamics
    • 4.3.1. Drivers
    • 4.3.2. Restraints
    • 4.3.3. Opportunities
  • 4.4. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, 2022-2031

5. Key Insights

  • 5.1. Pipeline Analysis
  • 5.2. COVID-19 Pandemic Impact on Industry

6. Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Treatment Type

  • 6.1. Introduction and Definitions
  • 6.2. Key Findings/Developments
  • 6.3. Market Value Forecast, by Treatment Type, 2023-2031
    • 6.3.1. Serotonin Antagonists
    • 6.3.2. Steroids
    • 6.3.3. Dopamine Antagonists
    • 6.3.4. NK-1 Receptor Antagonists
    • 6.3.5. Non-pharmacologic Treatment
    • 6.3.6. Others
  • 6.4. Market Attractiveness, by Treatment Type

7. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Distribution Channel

  • 7.1. Introduction and Definitions
  • 7.2. Key Findings/Developments
  • 7.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online Pharmacies
    • 7.3.3. Retail Pharmacies & Drug Stores
  • 7.4. Market Attractiveness, by Distribution Channel

8. Global Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast, by Region

  • 8.1. Key Findings
  • 8.2. Market Value Forecast, by Region, 2023-2031
    • 8.2.1. North America
    • 8.2.2. Europe
    • 8.2.3. Asia Pacific
    • 8.2.4. Latin America
    • 8.2.5. Middle East & Africa
  • 8.3. Market Attractiveness, by Region

9. North America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 9.1. Introduction
    • 9.1.1. Key Findings
  • 9.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 9.2.1. Serotonin Antagonists
    • 9.2.2. Steroids
    • 9.2.3. Dopamine Antagonists
    • 9.2.4. NK-1 Receptor Antagonists
    • 9.2.5. Non-pharmacologic Treatment
    • 9.2.6. Others
  • 9.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online Pharmacies
    • 9.3.3. Retail Pharmacies & Drug Stores
  • 9.4. Market Value Forecast, by Country, 2023-2031
    • 9.4.1. U.S.
    • 9.4.2. Canada
  • 9.5. Market Attractiveness Analysis
    • 9.5.1. By Treatment Type
    • 9.5.2. By Distribution Channel
    • 9.5.3. By Country

10. Europe Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 10.1. Introduction
    • 10.1.1. Key Findings
  • 10.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 10.2.1. Serotonin Antagonists
    • 10.2.2. Steroids
    • 10.2.3. Dopamine Antagonists
    • 10.2.4. NK-1 Receptor Antagonists
    • 10.2.5. Non-pharmacologic Treatment
    • 10.2.6. Others
  • 10.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online Pharmacies
    • 10.3.3. Retail Pharmacies & Drug Stores
  • 10.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 10.4.1. Germany
    • 10.4.2. U.K.
    • 10.4.3. France
    • 10.4.4. Italy
    • 10.4.5. Spain
    • 10.4.6. Rest of Europe
  • 10.5. Market Attractiveness Analysis
    • 10.5.1. By Treatment Type
    • 10.5.2. By Distribution Channel
    • 10.5.3. By Country/Sub-region

11. Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 11.1. Introduction
    • 11.1.1. Key Findings
  • 11.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 11.2.1. Serotonin Antagonists
    • 11.2.2. Steroids
    • 11.2.3. Dopamine Antagonists
    • 11.2.4. NK-1 Receptor Antagonists
    • 11.2.5. Non-pharmacologic Treatment
    • 11.2.6. Others
  • 11.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 11.3.1. Hospital Pharmacies
    • 11.3.2. Online Pharmacies
    • 11.3.3. Retail Pharmacies & Drug Stores
  • 11.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 11.4.1. China
    • 11.4.2. Japan
    • 11.4.3. India
    • 11.4.4. Australia & New Zealand
    • 11.4.5. Rest of Asia Pacific
  • 11.5. Market Attractiveness Analysis
    • 11.5.1. By Treatment Type
    • 11.5.2. By Distribution Channel
    • 11.5.3. By Country/Sub-region

12. Latin America Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 12.1. Introduction
    • 12.1.1. Key Findings
  • 12.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 12.2.1. Serotonin Antagonists
    • 12.2.2. Steroids
    • 12.2.3. Dopamine Antagonists
    • 12.2.4. NK-1 Receptor Antagonists
    • 12.2.5. Non-pharmacologic Treatment
    • 12.2.6. Others
  • 12.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 12.3.1. Hospital Pharmacies
    • 12.3.2. Online Pharmacies
    • 12.3.3. Retail Pharmacies & Drug Stores
  • 12.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 12.4.1. Brazil
    • 12.4.2. Mexico
    • 12.4.3. Rest of Latin America
  • 12.5. Market Attractiveness Analysis
    • 12.5.1. By Treatment Type
    • 12.5.2. By Distribution Channel
    • 12.5.3. By Country/Sub-region

13. Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Analysis and Forecast

  • 13.1. Introduction
    • 13.1.1. Key Findings
  • 13.2. Market Value Forecast, by Treatment Type, 2023-2031
    • 13.2.1. Serotonin Antagonists
    • 13.2.2. Steroids
    • 13.2.3. Dopamine Antagonists
    • 13.2.4. NK-1 Receptor Antagonists
    • 13.2.5. Non-pharmacologic Treatment
    • 13.2.6. Others
  • 13.3. Market Value Forecast, by Distribution Channel, 2023-2031
    • 13.3.1. Hospital Pharmacies
    • 13.3.2. Online Pharmacies
    • 13.3.3. Retail Pharmacies & Drug Stores
  • 13.4. Market Value Forecast, by Country/Sub-region, 2023-2031
    • 13.4.1. GCC Countries
    • 13.4.2. South Africa
    • 13.4.3. Rest of Middle East & Africa
  • 13.5. Market Attractiveness Analysis
    • 13.5.1. By Treatment Type
    • 13.5.2. By Distribution Channel
    • 13.5.3. By Country/Sub-region

14. Competition Landscape

  • 14.1. Market Player - Competition Matrix (By Tier and Size of Companies)
  • 14.2. Market Share Analysis, by Company (2022)
  • 14.3. Company Profiles
    • 14.3.1. Acacia Pharma
      • 14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.1.2. Product Portfolio
      • 14.3.1.3. Financial Overview
      • 14.3.1.4. SWOT Analysis
      • 14.3.1.5. Strategic Overview
    • 14.3.2. F. Hoffmann-La Roche AG
      • 14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.2.2. Product Portfolio
      • 14.3.2.3. Financial Overview
      • 14.3.2.4. SWOT Analysis
      • 14.3.2.5. Strategic Overview
    • 14.3.3. Novartis AG
      • 14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.3.2. Product Portfolio
      • 14.3.3.3. Financial Overview
      • 14.3.3.4. SWOT Analysis
      • 14.3.3.5. Strategic Overview
    • 14.3.4. Ani Pharmaceuticals, Inc.
      • 14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.4.2. Product Portfolio
      • 14.3.4.3. Financial Overview
      • 14.3.4.4. SWOT Analysis
      • 14.3.4.5. Strategic Overview
    • 14.3.5. Camurus AB
      • 14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.5.2. Product Portfolio
      • 14.3.5.3. Financial Overview
      • 14.3.5.4. SWOT Analysis
      • 14.3.5.5. Strategic Overview
    • 14.3.6. Sanofi S.A.
      • 14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.6.2. Product Portfolio
      • 14.3.6.3. Financial Overview
      • 14.3.6.4. SWOT Analysis
      • 14.3.6.5. Strategic Overview
    • 14.3.7. Helsinn Holding S.A.
      • 14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.7.2. Product Portfolio
      • 14.3.7.3. Financial Overview
      • 14.3.7.4. SWOT Analysis
      • 14.3.7.5. Strategic Overview
    • 14.3.8. Eisai Corporation
      • 14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.8.2. Product Portfolio
      • 14.3.8.3. Financial Overview
      • 14.3.8.4. SWOT Analysis
      • 14.3.8.5. Strategic Overview
    • 14.3.9. GlaxoSmithKline Corporation
      • 14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.9.2. Product Portfolio
      • 14.3.9.3. Financial Overview
      • 14.3.9.4. SWOT Analysis
      • 14.3.9.5. Strategic Overview
    • 14.3.10. Merck and Co.
      • 14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
      • 14.3.10.2. Product Portfolio
      • 14.3.10.3. Financial Overview
      • 14.3.10.4. SWOT Analysis
      • 14.3.10.5. Strategic Overview

List of Tables

  • Table 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 02: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 03: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Region, 2023-2031
  • Table 04: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 05: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 06: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country, 2023-2031
  • Table 07: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 08: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 09: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 10: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 11: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 12: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 13: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 14: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 15: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031
  • Table 16: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Treatment Type, 2023-2031
  • Table 17: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Distribution Channel, 2023-2031
  • Table 18: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023-2031

List of Figures

  • Figure 01: Global Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 02: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 03: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 04: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 05: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 06: Global Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Region, 2022 and 2031
  • Figure 07: Global Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Region, 2023-2031
  • Figure 08: North America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 09: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 10: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 11: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 12: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 13: North America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country, 2022 and 2031
  • Figure 14: North America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country, 2023-2031
  • Figure 15: Europe Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 16: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 17: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 18: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 19: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 20: Europe Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 21: Europe Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 22: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 23: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 24: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 25: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 26: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 27: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 28: Asia Pacific Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 29: Latin America Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 30: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 31: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 32: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 33: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 34: Latin America Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 35: Latin America Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 36: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value (US$ Mn) Forecast, 2023-2031
  • Figure 37: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Treatment Type, 2022 and 2031
  • Figure 38: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Treatment Type, 2023-2031
  • Figure 39: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Distribution Channel, 2022 and 2031
  • Figure 40: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Distribution Channel, 2023-2031
  • Figure 41: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Value Share Analysis, by Country/Sub-region, 2022 and 2031
  • Figure 42: Middle East & Africa Post-operative Nausea and Vomiting (PONV) Market Attractiveness Analysis, by Country/Sub-region, 2023-2031
  • Figure 43: Global Post-operative Nausea and Vomiting (PONV) Market Share Analysis, by Company, 2022